Rafferty Asset Management LLC Has $1.54 Million Stake in Insulet Co. (NASDAQ:PODD)

Rafferty Asset Management LLC cut its holdings in Insulet Co. (NASDAQ:PODDFree Report) by 2.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,110 shares of the medical instruments supplier’s stock after selling 172 shares during the period. Rafferty Asset Management LLC’s holdings in Insulet were worth $1,543,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in PODD. Parkside Financial Bank & Trust lifted its holdings in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 123 shares during the last quarter. Wolff Wiese Magana LLC raised its stake in Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in Insulet in the 4th quarter valued at $34,000. Jones Financial Companies Lllp acquired a new stake in Insulet in the 4th quarter worth $40,000. Finally, Lindbrook Capital LLC increased its holdings in shares of Insulet by 64.1% during the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PODD shares. Barclays reduced their target price on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research report on Tuesday, May 7th. Raymond James reduced their target price on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. Jefferies Financial Group boosted their price target on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Piper Sandler reduced their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $239.18.

Get Our Latest Stock Report on PODD

Insider Buying and Selling

In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total value of $596,970.00. Following the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at $7,703,807.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

Insulet stock opened at $192.04 on Tuesday. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $298.95. The stock has a 50-day simple moving average of $174.92 and a 200 day simple moving average of $185.48. The company has a quick ratio of 2.75, a current ratio of 3.74 and a debt-to-equity ratio of 1.72. The stock has a market capitalization of $13.45 billion, a price-to-earnings ratio of 58.19, a P/E/G ratio of 3.45 and a beta of 1.15.

Insulet (NASDAQ:PODDGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.34. The firm had revenue of $441.70 million during the quarter, compared to analysts’ expectations of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. Insulet’s revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.23 EPS. On average, research analysts anticipate that Insulet Co. will post 3.11 earnings per share for the current fiscal year.

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Further Reading

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.